Ticagrelor No Better Than Clopidogrel In Peripheral Artery Disease
AstraZeneca announces top-line results from EUCLID trial ahead of the AHA. Ticagrelor is no better than clopidogrel in patients who have peripheral artery disease, a large new study will show. On Tuesday morning AstraZeneca announced the top line results of the EUCLID (Examining Use of Ticagrelor in PAD) trial. The full results will be presented...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - October 4, 2016 Category: Cardiology Authors: Larry Husten Tags: MI/ACS People, Places & Events clopidogrel EUCLID peripheral artery disease ticagrelor Source Type: blogs
More Blasts Of Concern Over ROCKET-AF
The controversy over the big Xarelto trial does not appear to be going away. A new investigation published in the BMJ raises more troubling questions about the ROCKET-AF trial, which compared the novel oral anticoagulant rivaroxaban (Xarelto, Johnson & Johnson) to warfarin in patients with atrial fibrillation. The controversy about the trial first unfolded last...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 28, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Alere BMJ INR rivaroxaban ROCKET-AF Xarelto Source Type: blogs
NIH Funds Second Round Of Controversial Chelation Tria
–TACT2 will test chelation in heart attack patients with diabetes. The NIH has agreed to fund a second round of a highly controversial study testing the possible benefits of chelation therapy in heart attack patients with diabetes. The second Trial to Assess Chelation Therapy (TACT2), now recruiting patients at more than 100 clinical sites, is...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 27, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events Policy & Ethics alternative medicine chelation diabetes drugs TACT Source Type: blogs
Zombie Lab Sues Former Execs, Owners, And Sales Force
–Yet more fallout from the catastrophic bankruptcy of HDL Lab The Zombie Lab case just got even messier. Last Friday the trustee for the bankrupt Health Diagnostic Laboratory (HDL) filed a massive lawsuit against the former executives, owners, sales force members, and others who profited from HDL. The 205-page lawsuit includes a detailed narrative of...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 21, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics bankruptcy DOJ HDL True Health Diagnostics zombie lab Source Type: blogs
Debate: Switching From Standard HF Therapy To Entresto
–A debate at the HFSA in Orlando over whether all patients tolerating standard therapy should be switched to Entresto. Editor’s Note: Heart failure specialist Eiran Z. Gorodeski (Cleveland Clinic) wrote this account of an important debate on Monday at the Heart Failure Society of America meeting in Orlando. Should every ambulatory patient tolerating moderate-dose ACEI/ARB...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 21, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics ARNI Entresto HFSA LCZ Source Type: blogs
American Heart Association and American Society Of Hypertension Explore Merger
–The two US blood pressure societies want to become ‘a single force multiplier in the fight against hypertension’ The American Heart Association (AHA) and the American Society of Hypertension (ASH) are officially exploring a merger. In a message sent to ASH members, ASH president John Bisognano (University of Rochester) said that “for the past several...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 20, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes american heart association American Society of Hypertension Source Type: blogs
Zombie Lab Company Sics Bill Collectors On Doctors Who Took Kickbacks
–The liquidating trustee for HDL Lab is seeking to reclaim kickbacks paid to doctors who ordered the company’s tests. Many doctors who ordered tests in the past from Health Diagnostic Laboratory (HDL) are now opening some unexpected and very unwelcome letters. HDL was the billion dollar lab company with a meteoric rise and an even...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 18, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Health Diagnostic Laboratory kickbacks zombie lab company Source Type: blogs
The Lancet Versus BMJ: Dispatch From The Statin Wars
–The editors of the two top UK medical journals are in a bitter fight over statins. The editors of the two top medical journals in the UK are at war over statins. The bitter fight has its origins in the 2014 publication in the BMJ of two articles that were highly critical of statins. Rory...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 15, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes BMJ guidelines Lancet retractions statins Source Type: blogs
SPRINTing to Lower BP Targets? Not So Fast
–Hypertension experts disagree about how to apply SPRINT results in the real world. Once again blood pressure experts are disagreeing about how to interpret SPRINT and how its results should be applied in the real world. A new study claims that applying the SPRINT results to US patients who meet SPRINT criteria would prevent more...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 15, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes blood pressure guidelines hypertension SPRINT targets Source Type: blogs
How Sweet: Sugar Industry Made Fat the Villain
–Harvard researchers received sugar industry money to write a NEJM review. Newly uncovered documents reveal that 50 years ago the sugar industry gave secret support to prominent Harvard researchers to write an influential series of articles in the New England Journal of Medicine that downplayed the negative effects of sugar. Instead, the articles shifted the blame...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 13, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes carbohydrates cholesterol diet low carb diet nutrition sugar Source Type: blogs
Guest Post: JACC Retracts AF Ablation Trial
Editor’s note: This guest post by Dalmeet Singh Chawla is reprinted with the permission of Retraction Watch, where it was originally published in a slightly different form. –Lead author Andrea Natale claims undue industry influence. The Journal of the American College of Cardiology (JACC) has retracted a recently published paper that questioned the effectiveness of a treatment for atrial...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 12, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms People, Places & Events Policy & Ethics AF ablation retraction rotos Topera Source Type: blogs
Statin Trialists Seek To Bury Debate With Evidence
–A Lancet review claims overwhelming evidence in favor of statins for both primary and secondary prevention. Some disagree. A large group of statin researchers argue forcefully that the debate over statins should be ended because the evidence in favor of statins is overwhelming and incontrovertible. But some outsiders say the issue is more nuanced and...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 8, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Evidence-based medicine open data primary prevention secondary prevention statins Source Type: blogs
SPRINT: More Controversy And Confusion About ‘ Landmark ’ Trial
–Blood pressure experts raise new questions and concerns about the controversial trial. More questions and concerns are being raised about SPRINT, the NIH’s “landmark” blood pressure lowering trial. In sharp contrast to the enormous amount of initial hype, many hypertension experts are now saying that the SPRINT trial is difficult to interpret and can’t be readily...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - September 6, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes blood pressure guidelines hypertension NIH SPRINT Source Type: blogs
Experts Weigh In On The Decline In Cardiovascular Drug Development
–CV disease is the top killer but pharma is pulling back on developing new drugs. Although cardiovascular disease is the number one cause of death in the world fewer cardiovascular drugs are under development now than in the past, according to a study published in JACC: Basic to Translational Science. Thomas Hwang and colleagues at...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - August 30, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Drug development FDA Source Type: blogs
New Heart Failure Drug Struggles To Find Its Footing
–Experts offer insight about Entresto at the ESC. Despite its success in a large and widely praised clinical trial the novel heart failure drug Entresto (sacubitril/valsartan, Novartis) has been struggling to gain a substantial foothold in the marketplace. Now new papers and presentations and commentary from experts at the European Society of Cardiology meeting are...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - August 29, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure Policy & Ethics cost effectiveness Entresto LCZ 696 PARADIGM Source Type: blogs
